IHI: building broad, bold collaborations – a word from our director
Broad, bold collaborations are the essence of IHI. We build collaborations that bring together Europe's scientific excellence with the research, engineering and product development capabilities of Europe's pharmaceutical and medical device industries to take on large, ambitious projects that no single organisation can tackle alone.
The call 11 topic on precision medicine for brain dysfunction is a great example. Imagine if depression, Alzheimer’s disease or obesity could be assessed with the precise diagnostic tools that have transformed oncology over the last 25 years. If treatments could be developed to directly address the underlying causes of the disease, rather than the symptoms that people are experiencing. This is a difficult field, and true to the spirit of IHI, we are looking for bold, ambitious, cross-sectorial collaborations.
IHI is a unique model for cross-sectorial collaboration, with the ability to mobilise broad coalitions for impactful projects. This is attracting both attention and investments from beyond the EU, and as you can read in this newsletter, in call 11 we are very happy to work with several European and global philanthropic organisations and draw on their strengths and deep engagement in civil society to launch a set of truly transformative projects.
Niklas Blomberg, IHI Executive Director
The call 11 topic on precision medicine for brain dysfunction is a great example. Imagine if depression, Alzheimer’s disease or obesity could be assessed with the precise diagnostic tools that have transformed oncology over the last 25 years. If treatments could be developed to directly address the underlying causes of the disease, rather than the symptoms that people are experiencing. This is a difficult field, and true to the spirit of IHI, we are looking for bold, ambitious, cross-sectorial collaborations.
IHI is a unique model for cross-sectorial collaboration, with the ability to mobilise broad coalitions for impactful projects. This is attracting both attention and investments from beyond the EU, and as you can read in this newsletter, in call 11 we are very happy to work with several European and global philanthropic organisations and draw on their strengths and deep engagement in civil society to launch a set of truly transformative projects.
Niklas Blomberg, IHI Executive Director
IHI call 11 open for applications
IHI call 11 is a two-stage call with topics on brain dysfunction, the link between infections and non-communicable diseases, AI and pharmacovigilance, type 1 diabetes, and ambulatory surgical centres.
Deadline: 9 October 2025
Find out more
Deadline: 9 October 2025
Catch up on the IHI Call Days for call 11
The IHI Call Days, which run until 30 June, feature online info sessions on all call topics as well as the rules and procedures for the call. The recordings and presentations are all available online.
The strategic value of philanthropic organisations in public-private partnerships
Philanthropic organisations are contributing significantly to IHI call 11. Here, they explain why IHI is well placed to enable public, private and philanthropic partners to work together strategically.
IHI Brokerage Event 2025 – save the date!
The IHI Brokerage Event 2025 will take place in Brussels, Belgium on 4-5 November. If you’re interested in future IHI calls, this is the ideal place to network and start building consortia.
Find out more
New Nature Reviews Drug Discovery paper highlights how to maximise the regulatory impact of consortia
The paper, by authors from IHI and the Critical Path Institute, highlights the importance of a structured, strategic approach to regulatory issues from the beginning.
Going green: meet the projects boosting the environmental performance of the health sector
IMI and IHI projects are tackling the environmental impacts of the sector, from the use of water, energy and raw materials to pollution and waste management.
IHI an IMI projects are closing the gender gap in health
IHI and IMI projects are investigating safe medicine use in pregnancy, cancers and autoimmune diseases that primarily affect women, and sex-based differences in autism.
Getting medicine to children with cancer faster with ITCC-P4
Children with cancer can’t wait for new drugs. ITCC-P4 is accelerating how quickly they come to the market via a non-profit association.
Can an AI helper assist skilled specialists? The SHERPA project thinks so
New IHI project SHERPA focuses on interventional radiologists, who use imaging technologies to guide miniature devices through a patient’s body.
Collaborating for cardiovascular care
GRACE is a new IHI project that aims to deliver a smoother care pathway for cardiovascular diseases, from diagnosis to treatment and long-term management.